Literature DB >> 8013780

[Reproducibility of histological criteria of dysplasia in Barrett mucosa].

C Sagan1, J F Fléjou, M D Diebold, F Potet, M F Le Bodic.   

Abstract

Barrett's mucosa is a precancerous condition. The goal of endoscopic surveillance for patients with Barrett's esophagus is to grade dysplasia. The diagnosis of dysplasia is difficult. The aim of this study was to determine the observer variation in diagnosis of dysplasia. Thirty-seven biopsies selected from Barrett's mucosa reported as having dysplasia between 1987 and 1988 were reviewed by 4 pathologists. The biopsies were classified according to the method of Riddell, as no dysplasia, indefinite for dysplasia, low-grade dysplasia and high-grade dysplasia. Each pathologist reviewed the biopsies alone and then together. There was a total agreement between the 4 pathologists in 20 out of 37 biopsies (54%). The pair-wise agreement varied between 65 and 84%. It was 84% when the pathologists belonged to the same institution. Of 222 double reviews made by 6 pairs of pathologists (37 biopsies x 6 pairs of pathologists), there were 58 disagreements: 19 low grade/high grade dysplasia, 2 high grade/indefinite for dysplasia, 1 high grade/no dysplasia, 18 low grade/indefinite for dysplasia, 2 low grade/no dysplasia, 16 indefinite for dysplasia/no dysplasia. At the second review when the pathologists evaluated the biopsies together, the agreement was 92%; there were 3 biopsies on which there was total disagreement: twice between high grade and low grade dysplasia, once between low grade dysplasia, indefinite for dysplasia and no dysplasia. This retrospective study has shown that disagreement between pathologists was rarely found on the biopsies diagnosed as having high grade dysplasia, more often on those diagnosed as having low grade dysplasia or indefinite for dysplasia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8013780

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  8 in total

1.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies.

Authors:  J P A Baak; F J W ten Kate; G J A Offerhaus; J J van Lanschot; G A Meijer
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

3.  Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.

Authors:  Linda M Dong; Alan R Kristal; Ulrike Peters; Jeannette M Schenk; Carissa A Sanchez; Peter S Rabinovitch; Patricia L Blount; Robert D Odze; Kamran Ayub; Brian J Reid; Thomas L Vaughan
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

4.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors:  P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

5.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

6.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.

Authors:  B J Reid; D S Levine; G Longton; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

Review 7.  A cost-utility analysis of ablative therapy for Barrett's esophagus.

Authors:  John M Inadomi; Ma Somsouk; Ryan D Madanick; Jennifer P Thomas; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2009-03-06       Impact factor: 22.682

8.  Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.

Authors:  Deepak V Gopal; David A Lieberman; Nathan Magaret; M Brian Fennerty; Richard E Sampliner; Harinder S Garewal; Gary W Falk; Douglas O Faigel
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.